Short Interest in Revelation Biosciences, Inc. (NASDAQ:REVB) Declines By 43.6%

Revelation Biosciences, Inc. (NASDAQ:REVB) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 18,500 shares, a decrease of 43.6% from the March 31st total of 32,800 shares. Based on an average daily volume of 391,900 shares, the short-interest ratio is currently 0.0 days. Currently, 1.1% of the shares of the company are sold short.

Revelation Biosciences Stock Up 1.9 %

Shares of NASDAQ:REVB traded up $0.04 during trading on Friday, hitting $2.18. The stock had a trading volume of 45,620 shares, compared to its average volume of 315,485. Revelation Biosciences has a 12-month low of $1.78 and a 12-month high of $39.00. The stock has a market capitalization of $3.55 million, a price-to-earnings ratio of 0.07 and a beta of 0.11. The stock has a 50-day simple moving average of $2.68 and a two-hundred day simple moving average of $10.90.

Revelation Biosciences (NASDAQ:REVB) last posted its quarterly earnings results on Friday, March 22nd. The company reported ($8.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($10.94) by $2.61. As a group, sell-side analysts forecast that Revelation Biosciences will post -20.32 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Revelation Biosciences stock. Sabby Management LLC raised its stake in Revelation Biosciences, Inc. (NASDAQ:REVB) by 14.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 403,233 shares of the company’s stock after acquiring an additional 50,000 shares during the quarter. Revelation Biosciences makes up approximately 0.2% of Sabby Management LLC’s investment portfolio, making the stock its 20th largest position. Sabby Management LLC owned approximately 6.40% of Revelation Biosciences worth $278,000 at the end of the most recent reporting period. 12.80% of the stock is owned by hedge funds and other institutional investors.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease.